Table 1 Baseline patient characteristics (ITT population)
From: A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia
1 L treatmenta ITT | Imatinib N = 26 | Nilotinib N = 27 | Dasatinib N = 8 | Ponatinib N = 1 | Imatinib (gen) N = 1 | Total N = 63 |
|---|---|---|---|---|---|---|
Men, n (%) | 13 (50) | 15 (56) | 6 (75) | 1 (100) | 0 (0) | 35 (56) |
Median age at diagnosis, years (IQR) | 60 (40–75) | 45 (38–65) | 56 (50–61) | 74 | 24 | 55 (40–68) |
Sokal risk group at diagnosis, % | ||||||
Low | 15 | 26 | 0 | 0 | 0 | N.A. |
Intermediate | 42 | 26 | 63 | 100 | 0 | |
High | 27 | 37 | 38 | 0 | 0 | |
Unknown | 15 | 11 | 0 | 0 | 100 | |
Median Sokal score at diagnosis, score (IQR), n | 1.04 (0.92–1.43), n = 19 | 1.16 (0.83–1.46), n = 16 | 1.14 (0.86–1.83), n = 6 | – , n = 0 | – , n = 0 | 1.10 (0.88–1.46), n = 41 |
Transcript type, n (%) | ||||||
e13a2 (b2a2) | 10 (38) | 9 (33) | 2 (25) | 0 (0) | 0 (0) | 21 (33) |
e14a2 (b3a2) | 12 (46) | 9 (33) | 5 (63) | 1 (100) | 0 (0) | 27 (43) |
both | 3 (12) | 1 (4) | 1 (12) | 0 (0) | 0 (0) | 5 (8) |
unknown | 1 (4) | 8 (30) | 0 (0) | 0 (0) | 1 (100) | 10 (16) |
Inclusion in clinical trial, n (%) | 1 (4) | 7 (26) | 0 (0) | 1 (100) | 0 (0) | 9 (14) |
Median daily dose, mg (IQR) | 400 (400–400) | 600 (600–600) | 100 (100–100) | 45 | 400 | – |